BPG is committed to discovery and dissemination of knowledge
Articles in Press
8/12/2020 7:05:11 PM | Browse: 111 | Download: 302
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sung Yong Han, Dong Uk Kim, Young Mi Seol, Suk Kim, Nam Kyung Lee, Seung Baek Hong and Hyung-Il Seo |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Research Foundation of Korea(NRF) grant funded by the Korea government (MSIT) |
NRF-2018R1C1B5086234 |
|
| Corresponding Author |
Dong Uk Kim, MD, PhD, Assistant Professor, Internal Medicine, Division of Gastroenterology, Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 49241, South Korea. amlm3@hanmail.net |
| Key Words |
Metastatic pancreatic carcinoma; Chemotherapy; FOLFIRINOX; Nab-paclitaxel plus gemcitabine; Predict marker; Adverse event |
| Core Tip |
Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. Our retrospective study aims to explore the efficacy and safety of FFX and GA as first-line chemotherapeutic regimens in patients with metastatic pancreatic cancer. Our data showed that comparable result in both regimens. However, GA regimen have better result of median progression free survival and overall survival in patients with ECOG 0 status or neutrophil/lymphocyte ratio <3. |
| Citation |
Han SY, Kim DU, Seol YM, Kim S, Lee NK, Hong SB, Seo HI. Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer. World J Clin Cases 2020; 8(17): 3718-3729 |
 |
Received |
|
2020-06-18 06:56 |
|
Peer-Review Started |
|
2020-06-18 06:57 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-07-24 23:52 |
|
Revised |
|
2020-07-28 10:40 |
|
Second Decision |
|
2020-08-12 11:46 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-08-12 19:05 |
|
Articles in Press |
|
2020-08-12 19:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-08-31 16:24 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
